Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Obstructive Hypertrophic Cardiomyopathy Clinical Trial

— MavaPET  

Official title:

Coronary Flow Reserve in oHCM Patients Before and After 12 Months of Standard-of-care Mavacamten Treatment as Assessed by PET/CT

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06023186
• Other study ID #: HSR220293
• Status: Not yet recruiting
• Start date: September 15, 2023
• Est. completion date: December 1, 2026

Study information

• Verified date: August 2023
• Source: University of Virginia
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is:

• Does mavacamten treatment improve blood flow in the heart muscle?

Participants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.

Description:

This is a single-arm, before-and-after investigation of the effect of mavacamten therapy on myocardial blood flows in adult human subjects prescribed mavacamten for clinical standard of care for oHCM. We hypothesize that 12 months of mavacamten therapy will improve myocardial blood flows as assessed by PET/CT. The investigation will take place at a single site. Participants who consent will be prospectively enrolled once mavacamten therapy has been approved by their health insurance/payer. Enrolled participants will undergo myocardial PET/CT before starting mavacamten and after 12 months of therapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: December 1, 2026
• Est. primary completion date: December 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Willingness and ability to provide written informed consent

2. Willingness and ability to comply with scheduled visits and study procedures

3. Male or female, aged 18-85 years

4. Diagnosed with obstructive hypertrophic cardiomyopathy according to presence of a left ventricular wall thickness of =15 mm that is otherwise unexplained by abnormal loading conditions (e.g., hypertension, valvular, congenital disease) or infiltrative cardiomyopathies. Unexplained left ventricular wall thickness of =13 mm is sufficient for diagnosis in relatives of individuals with hypertrophic cardiomyopathy or those who are genotype positive.

5. Has been prescribed mavacamten consistent with US Prescribing Information

6. Ability and intention to adhere to oral mavacamten therapy as prescribed by treating physician for the duration of study participation

7. For females of reproductive potential: negative pregnancy test at screening/baseline and 12 month visits.

Exclusion Criteria:

1. Pregnancy or lactation

2. Known hypersensitivity to components of mavacamten or regadenoson

3. Prior treatment with mavacamten or aficamten

11. Over weight limit for imaging gantry. 12. To minimize the risk of participants undergoing PET/CT with inadequate image quality, participants with left ventricular systolic dysfunction or lung disease will be excluded.

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Hypertrophic
• Obstructive Hypertrophic Cardiomyopathy

Intervention

Drug:
• mavacamten
Study participants will receive mavacamten under the standard of care

Locations

Country	Name	City	State
United States	University of Virginia	Charlottesville	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Michael Ayers	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in myocardial perfusion reserve after 12 months of mavacamten treatment.	Myocardial perfusion reserve is the ratio of global myocardial blood flow at stress versus rest.	12 months